Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy.

Moretti S, Cafaro A, Tripiciano A, Picconi O, Buttò S, Ensoli F, Sgadari C, Monini P, Ensoli B.

Expert Rev Vaccines. 2020 Jan;19(1):71-84. doi: 10.1080/14760584.2020.1712199. Epub 2020 Jan 19.

PMID:
31957513
2.

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Buttò S, Monini P, Ensoli B.

Vaccines (Basel). 2019 Aug 26;7(3). pii: E99. doi: 10.3390/vaccines7030099. Review.

3.

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, Bellino S, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B.

Front Immunol. 2019 Feb 13;10:233. doi: 10.3389/fimmu.2019.00233. eCollection 2019.

4.
5.

"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".

Cafaro A, Sgadari C, Picconi O, Tripiciano A, Moretti S, Francavilla V, Pavone Cossut MR, Buttò S, Cozzone G, Ensoli F, Monini P, Ensoli B.

Expert Rev Vaccines. 2018 Feb;17(2):115-126. doi: 10.1080/14760584.2018.1418666. Epub 2017 Dec 22. Review.

PMID:
29243498
6.

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.

Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group.

Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.

7.

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.

Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B.

Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.

PMID:
26096836
8.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

9.

Challenges in HIV Vaccine Research for Treatment and Prevention.

Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F.

Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. eCollection 2014. Review.

10.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

11.

Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.

Cenci A, D'Avenio G, Tavoschi L, Chiappi M, Becattini S, Narino Mdel P, Picconi O, Bernasconi D, Fanales-Belasio E, Vardas E, Sukati H, Lo Presti A, Ciccozzi M, Monini P, Ensoli B, Grigioni M, Buttò S.

PLoS One. 2014 Apr 30;9(4):e95183. doi: 10.1371/journal.pone.0095183. eCollection 2014.

12.

Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a.

Cortecchia S, Galanti G, Sgadari C, Costa S, De Lillo M, Caprara L, Barillari G, Monini P, Nannini R, Ensoli B, Bucchi L.

Int J Gynecol Cancer. 2013 Nov;23(9):1663-9. doi: 10.1097/IGC.0b013e3182a80b14.

PMID:
24172101
13.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

14.

Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.

Barillari G, Iovane A, Bacigalupo I, Palladino C, Bellino S, Leone P, Monini P, Ensoli B.

AIDS. 2012 May 15;26(8):909-19. doi: 10.1097/QAD.0b013e328351f7a5.

PMID:
22313963
15.

Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking.

Pierleoni R, Menotta M, Antonelli A, Sfara C, Serafini G, Dominici S, Laguardia ME, Salis A, Damonte G, Banci L, Porcu M, Monini P, Ensoli B, Magnani M.

Mol Cell Biochem. 2010 Dec;345(1-2):105-18. doi: 10.1007/s11010-010-0564-9. Epub 2010 Aug 20.

PMID:
20721684
16.

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.

Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B.

Int J Cancer. 2011 Jan 1;128(1):82-93. doi: 10.1002/ijc.25550.

17.

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.

Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B.

J Virol. 2010 Sep;84(17):8953-8. doi: 10.1128/JVI.00377-10. Epub 2010 Jun 16.

18.

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B.

Rev Recent Clin Trials. 2009 Sep;4(3):195-204. Review.

PMID:
20028332
19.

The preventive phase I trial with the HIV-1 Tat-based vaccine.

Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E.

Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29.

PMID:
19879233
20.

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, Ferrantelli F, Monini P, Ensoli F, Ensoli B.

Int Rev Immunol. 2009;28(5):285-334. doi: 10.1080/08830180903013026. Review.

PMID:
19811313
21.

HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.

Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B.

J Immunol. 2009 Mar 1;182(5):2888-97. doi: 10.4049/jimmunol.0711406.

22.

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B.

Vaccine. 2009 May 26;27(25-26):3306-12. doi: 10.1016/j.vaccine.2009.01.090. Epub 2009 Feb 7.

PMID:
19208456
23.

Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.

Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B.

AIDS. 2009 Feb 20;23(4):534-8. doi: 10.1097/QAD.0b013e3283262a8d.

PMID:
19169139
24.

Primary effusion lymphoma cells undergoing human herpesvirus type 8 productive infection produce C-type retroviral particles.

Tinari A, Superti F, Ammendolia MG, Chiozzini C, Hohenadl C, Leone P, Nappi F, Nicoletti M, Borsetti A, Marchetti M, Ensoli B, Monini P.

Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):999-1006.

PMID:
19144286
25.

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.

Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E.

AIDS. 2008 Oct 18;22(16):2207-9. doi: 10.1097/QAD.0b013e32831392d4.

PMID:
18832884
26.

The use of HAART for biological tumour therapy.

Monini P, Toschi E, Sgadari C, Bacigalupo I, Palladino C, Carlei D, Barillari G, Ensoli B.

J HIV Ther. 2006 Sep;11(3):53-6. Review. No abstract available.

PMID:
17580499
27.

Combined effect of apolipoprotein e genotype and past fertility on age at onset of Alzheimer's disease in women.

Corbo RM, Gambina G, Ulizzi L, Monini P, Broggio E, Rosano A, Scacchi R.

Dement Geriatr Cogn Disord. 2007;24(2):82-5. Epub 2007 Jun 12.

PMID:
17565217
28.

Control of human herpes virus type 8-associated diseases by NK cells.

Sirianni MC, Campagna M, Scaramuzzi D, Carbonari M, Toschi E, Bacigalupo I, Monini P, Ensoli B.

Ann N Y Acad Sci. 2007 Jan;1096:37-43.

PMID:
17405914
29.

Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.

Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Buttò S, Monini P, Magnani M, Caputo A, Garaci E.

AIDS. 2006 Nov 28;20(18):2245-61. Review. No abstract available.

PMID:
17117011
30.

Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.

Simonelli C, Talamini R, Bearz A, Berretta M, Spazzapan S, Monini P, Sgadari C, Sartor I, Ensoli B, Tirelli U.

Ann Oncol. 2006 Aug;17(8):1335-6. Epub 2006 Mar 28. No abstract available.

31.

Identification of CD8+ T cell epitopes within lytic antigens of human herpes virus 8.

Ribechini E, Fortini C, Marastoni M, Traniello S, Spisani S, Monini P, Gavioli R.

J Immunol. 2006 Jan 15;176(2):923-30.

32.

Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development.

Sirianni MC, Libi F, Campagna M, Rossi D, Capello D, Sciaranghella G, Carbone A, Simonelli C, Monini P, Gaidano G, Ensoli B.

Br J Haematol. 2005 Jul;130(1):92-5. Erratum in: Br J Haematol. 2005 Oct;131(2):282.

PMID:
16044583
33.

Antitumour effects of antiretroviral therapy.

Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B.

Nat Rev Cancer. 2004 Nov;4(11):861-75. Review.

PMID:
15516959
34.

CD8(+)CD28(-) T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features.

Alessandri G, Fiorentini S, Licenziati S, Bonafede M, Monini P, Ensoli B, Caruso A.

J Interferon Cytokine Res. 2003 Sep;23(9):523-31.

PMID:
14565861
35.

Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.

Sgadari C, Monini P, Barillari G, Ensoli B.

Lancet Oncol. 2003 Sep;4(9):537-47. Review.

PMID:
12965274
36.

HIV protease inhibitors as new treatment options for Kaposi's sarcoma.

Barillari G, Sgadari C, Toschi E, Monini P, Ensoli B.

Drug Resist Updat. 2003 Aug;6(4):173-81.

PMID:
12962683
37.

[HIV protease inhibitors for the treatment of Kaposi's sarcoma].

Grosso G, Sgadari C, Barillari G, Toschi E, Bacigalupo I, Carlei D, Palladino C, Baccarini S, Malavasi L, Moracci G, Leone P, Chiozzini C, Monini P, Ensoli B.

Recenti Prog Med. 2003 Feb;94(2):69-74. Review. Italian.

PMID:
12908373
38.

HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.

Monini P, Sgadari C, Barillari G, Ensoli B.

J Antimicrob Chemother. 2003 Feb;51(2):207-11. Review. No abstract available.

PMID:
12562682
39.

Treatment of Kaposi's sarcoma--an update.

Toschi E, Sgadari C, Monini P, Barillari G, Bacigalupo I, Palladino C, Baccarini S, Carlei D, Grosso G, Sirianni MC, Ensoli B.

Anticancer Drugs. 2002 Nov;13(10):977-87. Review.

PMID:
12439331
40.

NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma.

Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, Scaramuzzi D, Andreoni M, Pinter E, Baccarini S, Rezza G, Monini P, Ensoli B.

Eur J Immunol. 2002 Oct;32(10):2711-20.

41.

Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.

Malnati M, Broccolo F, Nozza S, Sarmati L, Ghezzi S, Locatelli G, Delfanti F, Capiluppi B, Careddu A, Andreoni M, Monini P, Poli G, Lazzarin A, Lusso P, Tambussi G.

Blood. 2002 Sep 1;100(5):1575-8.

PMID:
12176873
42.

Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.

Micheletti F, Monini P, Fortini C, Rimessi P, Bazzaro M, Andreoni M, Giuliani M, Traniello S, Ensoli B, Gavioli R.

Immunology. 2002 Jul;106(3):395-403.

43.

A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area.

Serraino D, Toma L, Andreoni M, Buttò S, Tchangmena O, Sarmati L, Monini P, Franceschi S, Ensoli B, Rezza G.

Eur J Epidemiol. 2001;17(9):871-6.

PMID:
12081107
44.

Onset of non-AIDS Kaposi sarcoma during therapy with interferon alfa-2a in an 82-year-old man with concomitant cutaneous T-cell lymphoma.

Giuliani M, Mastroianni A, Di Carlo A, Donati P, Miceli M, Monini P, Rezza G.

Arch Dermatol. 2002 Apr;138(4):535-7. No abstract available.

PMID:
11939825
45.

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.

Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B.

Nat Med. 2002 Mar;8(3):225-32.

PMID:
11875492
46.

Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients.

Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, Sarmati L, Farchi F, Tisone G, Piazza A, Pisani F, Angelico M, Leone P, Citterio F, Ensoli B, Rezza G.

J Infect. 2001 Oct;43(3):195-9.

PMID:
11798259
47.

Human herpesvirus-8 and other viral infections, Papua New Guinea.

Rezza G, Danaya RT, Wagner TM, Sarmati L, Owen IL, Monini P, Andreoni M, Suligoi B, Ensoli B, Pozio E.

Emerg Infect Dis. 2001 Sep-Oct;7(5):893-5.

48.

Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report.

Monini P, Sirianni MC, Franco M, Vincenzi L, Topino S, Goletti D, Leone P, Leone P, Chiozzini C, Nicastri E, Andreoni M, Borduagni O, Sgadari C, Rezza G, Stürzl M, Ensoli B.

Clin Infect Dis. 2001 Nov 15;33(10):1782-5. Epub 2001 Oct 12.

PMID:
11641829
49.

Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor.

Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, Palladino C, Zietz C, Leone P, Stürzl M, Buttò S, Cafaro A, Monini P, Ensoli B.

Mol Biol Cell. 2001 Oct;12(10):2934-46.

50.

The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines.

Guenzi E, Töpolt K, Cornali E, Lubeseder-Martellato C, Jörg A, Matzen K, Zietz C, Kremmer E, Nappi F, Schwemmle M, Hohenadl C, Barillari G, Tschachler E, Monini P, Ensoli B, Stürzl M.

EMBO J. 2001 Oct 15;20(20):5568-77.

Supplemental Content

Loading ...
Support Center